Differential transcriptomic profiling of BCL2-related genes in primary tumor and metastatic sites of prostate cancer

Authors:

B.A. Carneiro1, J. Yin2, L. Soliman1, A. De Souza1, D. Golijanin3, A. Mega1, P.C. Barata4, S. Gulati5, S. Wei6, D. Geynisman7, D. Magee2, W.M. Korn2, I. Abuali5, E. Heath8, C.J. Ryan9, P. Bertone1, W.S. El-Deiry1;

BACKGROUND

  • BCL2-related anti-apoptotic (BCL-2, BCL-XL, MCL-1, BCL2A1, BCL2L10) and pro-apoptotic proteins (BAX, BAD, BID, BAK-1) regulate cellular sensitivity to apoptosis stimuli 1.
  • Overexpression of BCL2 and resistance to apoptosis have been implicated in the development of androgen-independent PCa and disease progression, which has clinical relevance given several therapeutic strategies targeting this pathway 2,3.
  • This project aimed to characterize the transcriptomic profile of BCL2-related genes and investigate distinct sensitivity to apoptosis between primary prostate tumors (PT) and metastatic sites (MS).

Download Publication